INCB24360 With Nivolumab In Select Advanced Cancers
A Phase 1/2 Study Of The Safety, Tolerability And Efficacy Of INCB24360 Administered In Combination With Nivolumab In Select Advanced Cancers
The primary purpose of this research study is to assess how safe and well tolerated the study drugs, INCB024360 and nivolumab, are when given in combination in patients who have advanced or metastatic solid tumors. The study will also assess how well INCB024360 in combination with nivolumab works in preventing disease progression patients with melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, head and neck squamous cell carcinoma, ovarian cancer and diffuse large B cell lymphoma.
Are you Eligible? (Inclusion Criteria)
1. Male or female subjects, age 18 years or older.
2. Subjects with histologically or cytologically confirmed NSCLC, MEL, CRC, SCCHN, ovarian cancer, and recurrent B cell NHL or HL.
3. Fresh baseline tumor biopsies are required. If a subject has inaccessible lesions, such as in ovarian cancer, this may be considered with medical monitor approval, and archived tissue may be acceptable.